Latest version offers a streamlined site-centric experience to simplify relationships with study sponsors.
Veeva Systems has announced the newest release of Veeva Site Connect. New capabilities of the solution are headlined by a streamlined site-centric experience that will simplify and standardize site-sponsor relationships.1
The solution offers sponsors and sites a single place to collaborate, automating information flow throughout the lifecycle of a clinical trial. Information flow includes protocols, safety reports, payment letters, and more.
New features of Veeva Site Connect include:
“By standardizing how information is shared across all sites in one application with Veeva Site Connect, we aim to save time and effort that can be focused on treating patients,” a clinical operations excellence leader at a top 20 biopharma said in a press release. “Our goal is to eliminate manual handoffs and inefficiencies for faster site start-up, more efficient monitoring, and simplified study closeout.”
Veeva Site Connect is part of Veeva Clinical Platform, which is the provider’s complete solution for patients, sites, and sponsors. According to Veeva, seven of the top 20 biopharmas have already adopted Site Connect.
“I would be ecstatic if all our sponsors use Veeva Site Connect. It gives sites a much more efficient way to collaborate with sponsors, maintain regulatory compliance, and get critical therapies to patients faster,” Alisha Garibaldi, CEO, Skylight Health Research, said in the press release. “The less time we spend doing administrative work in systems, the more time we have to execute trials and help patients.”
Marta Jureczko-Hinzmann, head of global clinical solution services at AstraZeneca added, “By implementing Veeva Site Connect for our safety letter distribution process, we anticipate achieving a significant reduction in manual processing while enhancing oversight and compliance. Sharing safety letters across all sites globally within a single application will allow us to harmonize the entire process across the company and optimize how we allocate valuable resources.”
This announcement from Veeva comes just days before its R&D Quality Summit which will be taking place in Boston, MA, September 9-10.
1. Major Release of Veeva Site Connect Streamlines Clinical Trial Execution for Sites and Sponsors. News release. Veeva Systems. September 5, 2024. Accessed September 5, 2024. https://www.veeva.com/resources/major-release-of-veeva-site-connect-streamlines-clinical-trial-execution-for-sites-and-sponsors/
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.